Bio-Path (BPTH) Competitors $0.12 -0.01 (-6.54%) As of 11:02 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. VRAX, ENTO, CERO, QLGN, RDHL, SLRX, VCNX, LIPO, PTIX, and SPRCShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Virax Biolabs Group (VRAX), Entero Therapeutics (ENTO), CERo Therapeutics (CERO), Qualigen Therapeutics (QLGN), Redhill Biopharma (RDHL), Salarius Pharmaceuticals (SLRX), Vaccinex (VCNX), Lipella Pharmaceuticals (LIPO), Atrinsic (PTIX), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors Virax Biolabs Group Entero Therapeutics CERo Therapeutics Qualigen Therapeutics Redhill Biopharma Salarius Pharmaceuticals Vaccinex Lipella Pharmaceuticals Atrinsic SciSparc Virax Biolabs Group (NASDAQ:VRAX) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Do analysts rate VRAX or BPTH? Virax Biolabs Group presently has a consensus target price of $3.00, indicating a potential upside of 428.17%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Bio-Path.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in VRAX or BPTH? 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to VRAX or BPTH? In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of -1.00 equaled Bio-Path'saverage media sentiment score. Company Overall Sentiment Virax Biolabs Group Negative Bio-Path Negative Which has more risk & volatility, VRAX or BPTH? Virax Biolabs Group has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Which has stronger valuation and earnings, VRAX or BPTH? Virax Biolabs Group has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K246.51-$6.06MN/AN/ABio-PathN/AN/A-$16.08MN/AN/A Is VRAX or BPTH more profitable? Virax Biolabs Group's return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Bio-Path N/A -2,842.40%-337.48% SummaryVirax Biolabs Group beats Bio-Path on 10 of the 10 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$997K$828.00M$5.77B$9.87BDividend YieldN/A4.84%6.67%4.51%P/E RatioN/A1.1375.6126.46Price / SalesN/A26.48551.64120.26Price / CashN/A19.5637.1158.92Price / Book0.176.7511.536.02Net Income-$16.08M-$4.20M$3.29B$266.38M7 Day Performance11.01%-0.18%-0.12%-0.53%1 Month Performance-17.18%10.61%6.12%3.30%1 Year Performance-87.53%27.60%60.95%22.81% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path0.5399 of 5 stars$0.12-6.5%N/A-86.7%$997KN/A0.0010Positive NewsGap UpVRAXVirax Biolabs Group2.4512 of 5 stars$0.76-0.5%$3.00+294.2%-84.7%$3.32M$10K0.005Short Interest ↑ENTOEntero TherapeuticsN/A$2.05+0.5%N/A+112.7%$3.24MN/A0.009Negative NewsShort Interest ↓Gap UpCEROCERo Therapeutics4.0633 of 5 stars$7.86-5.3%$45.00+472.5%-97.1%$3.21MN/A0.008News CoveragePositive NewsShort Interest ↓Gap DownQLGNQualigen TherapeuticsN/A$1.88+0.8%N/A-81.8%$3.15MN/A0.0050News CoverageShort Interest ↓RDHLRedhill BiopharmaN/A$1.37+4.6%N/A-85.9%$3.01M$8.04M0.00210News CoverageShort Interest ↓Gap UpSLRXSalarius Pharmaceuticals1.047 of 5 stars$5.62-2.6%N/A-79.1%$2.94MN/A-0.1320Short Interest ↓Gap DownVCNXVaccinex0.4438 of 5 stars$0.46-54.0%N/A-89.5%$2.76M$388K-0.0140Short Interest ↑Gap DownLIPOLipella Pharmaceuticals0.9245 of 5 stars$0.59+0.5%N/A-82.3%$2.74M$536.36K-0.154Short Interest ↑PTIXAtrinsic0.3013 of 5 stars$4.51+6.4%N/A-63.2%$2.50MN/A-0.342Short Interest ↑Gap DownSPRCSciSparc0.973 of 5 stars$4.22-8.9%N/A-69.3%$2.48M$1.31M0.004Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies VRAX Alternatives ENTO Alternatives CERO Alternatives QLGN Alternatives RDHL Alternatives SLRX Alternatives VCNX Alternatives LIPO Alternatives PTIX Alternatives SPRC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTH Stock Alerts